Nautilus Biotechnology Launches “First Access Challenge”
Open competition allows researchers to be among the first to access potentially groundbreaking proteomic data through the testing of twelve samples on Nautilus’ single-molecule protein analysis platform
SEATTLE, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the launch of the First Access Challenge, a research competition for high-impact work in single-molecule proteomics. Scientists of all backgrounds are invited to submit proposals and gain early access to Nautilus’ Proteome Analysis Platform.
“We are excited to launch the First Access Challenge with the goal of enabling researchers from a broad spectrum of disciplines to uncover new biological insights and explore new areas of the proteome at massive scale,” said Nautilus co-founder and Chief Scientist Parag Mallick.
Nautilus’ single-molecule, large-scale platform uses Protein Identification by Short-epitope Mapping (PrISM) with an aim of easily and sensitively measuring billions of intact proteins. Applications for the Challenge are welcomed across many fields, including oncology, neuroscience, cardiology, and immunology.
Details of the First Access Challenge
Three winning proposals will be selected in 2023 to receive a quantitative, single-molecule analysis of 12 samples in collaboration with Nautilus’ scientists, as well as a conference travel award to present the data and writing assistance for a peer-reviewed journal submission.
Scientists are invited to submit their abstracts through Nautilus’ website before the deadline of Friday, February 10, 2023. Submissions will be evaluated by the Nautilus team for their potential scientific impact, and the three winning proposals will be announced at the US HUPO 2023 Conference, which will be held in Chicago, IL on March 4-8, 2023.
For more detailed information, please see the FAQ section of the contest submission page.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a protein analysis platform for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, expectations with respect to the functionality and performance of Nautilus’ Proteome Analysis Platform, its potential to easily and sensitively measure billions of intact single molecule proteins, and its ability to enable scientific explorations and discovery. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2022 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.